API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Results from a recent pilot study showed that SJP-001, comprising a combination of naproxen and fexofenadine was significantly more effective in reducing alcohol hangover severity than placebo.
Lead Product(s): Naproxen,Fexofenadine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: SJP-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022